Collegium Pharmaceutical (COLL) Price Target Increased to $35.00 by Analysts at Needham & Company LLC

Collegium Pharmaceutical (NASDAQ:COLL) had its price objective hoisted by Needham & Company LLC from $28.00 to $35.00 in a report released on Wednesday morning, MarketBeat reports. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the stock. Janney Montgomery Scott set a $26.00 price objective on shares of Collegium Pharmaceutical and gave the company a buy rating in a report on Tuesday. Zacks Investment Research downgraded shares of Collegium Pharmaceutical from a buy rating to a hold rating in a report on Friday, February 2nd. HC Wainwright reaffirmed a buy rating and set a $21.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, November 17th. Piper Jaffray Companies reaffirmed a buy rating and set a $24.00 price objective on shares of Collegium Pharmaceutical in a report on Thursday, December 7th. Finally, Jefferies Group upped their price objective on shares of Collegium Pharmaceutical to $27.00 and gave the company a buy rating in a report on Tuesday, December 5th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. Collegium Pharmaceutical presently has a consensus rating of Buy and an average target price of $26.33.

Shares of Collegium Pharmaceutical (NASDAQ COLL) opened at $21.43 on Wednesday. Collegium Pharmaceutical has a fifty-two week low of $7.37 and a fifty-two week high of $26.77.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.73) by $0.28. The business had revenue of $11.95 million for the quarter, compared to the consensus estimate of $5.31 million. Collegium Pharmaceutical had a negative net margin of 447.83% and a negative return on equity of 77.11%. The company’s revenue was up 2814.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.13) earnings per share. sell-side analysts forecast that Collegium Pharmaceutical will post -2.5 earnings per share for the current year.

In other news, CEO Michael Thomas Heffernan sold 50,000 shares of the stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $15.53, for a total value of $776,500.00. Following the sale, the chief executive officer now directly owns 558,987 shares of the company’s stock, valued at $8,681,068.11. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Alison B. Fleming sold 4,601 shares of the stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $17.25, for a total transaction of $79,367.25. Following the completion of the sale, the insider now directly owns 28,513 shares in the company, valued at $491,849.25. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,105,558 shares of company stock worth $19,346,677. Insiders own 25.76% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. Nationwide Fund Advisors lifted its holdings in shares of Collegium Pharmaceutical by 27.8% in the second quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock worth $161,000 after buying an additional 2,802 shares in the last quarter. Royal Bank of Canada lifted its holdings in shares of Collegium Pharmaceutical by 12.7% in the second quarter. Royal Bank of Canada now owns 29,139 shares of the specialty pharmaceutical company’s stock worth $365,000 after buying an additional 3,285 shares in the last quarter. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Collegium Pharmaceutical by 87.5% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 7,500 shares of the specialty pharmaceutical company’s stock worth $138,000 after buying an additional 3,500 shares in the last quarter. Teton Advisors Inc. lifted its holdings in shares of Collegium Pharmaceutical by 18.5% in the fourth quarter. Teton Advisors Inc. now owns 32,000 shares of the specialty pharmaceutical company’s stock worth $591,000 after buying an additional 5,000 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in shares of Collegium Pharmaceutical by 12.8% in the third quarter. Wells Fargo & Company MN now owns 45,254 shares of the specialty pharmaceutical company’s stock worth $475,000 after buying an additional 5,136 shares in the last quarter. 82.29% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This news story was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://sportsperspectives.com/2018/02/08/collegium-pharmaceutical-coll-price-target-increased-to-35-00-by-analysts-at-needham-company-llc.html.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply